Investors

MediPharm Labs is an international leader in the production and manufacturing of purified, pharmaceutical-quality cannabis extracts and goods.

We are committed to driving value for our investors by leveraging our credentials to continue to support the growing need for cannabinoid based API, globally.

Download the latest Presentation

Management and Board of Directors

Lorem ipsum dolor sit amet. Ut quam ipsa At dolore voluptatem aut voluptate laborum id aliquid ipsam ut fugiat quisquam. Qui quam galisum quo mollitia cumque nam voluptas saepe sit Quis soluta non corporis voluptatem et molestiae sint. Est consequatur corporis aut molestias similique hic Quis consequatur in quia autem rem soluta architecto qui modi sunt!

Chris Taves
Chairman of the board

Chris Taves was appointed Chief Operating Officer, BMO Capital Markets in January 2018. In this role, he has oversight of all balance sheet and risk taking activity, as well as regulatory, compliance, and operational functions to ensure they are optimized to satisfy client needs and BMO FG requirements.

Mr. Taves brings over 20 years of customer facing experience covering corporate and institutional clients across a wide range of products, including derivatives, investments, and corporate finance, working closely with I&CB and all areas within Trading Products. Since joining BMO in 2009, he has taken on broader mandates within the Trading Products team, most recently as Co-Head of Global Trading Products.

Mr. Taves is part of the BMO Capital Markets Operating and Executive Committees, the board of BMO Capital Market’s US broker-dealer – BMO Capital Markets Corp., the board of BMO China, and various other leadership committees within BMO Capital Markets and BMO Financial Group.

Mr. Taves holds an MBA from the Ivey School of Business at the University of Western Ontario, a Mathematics degree from the University of Waterloo, and is a Chartered Professional Accountant. He is a member of the United Way Toronto and York Region Major Individual Giving Cabinet and a Director on the board of Armagh, a second-stage housing program for abused women, Operating and Executive committees.

David Pidduck
Chief Executive Officer

David Pidduck joined MediPharm Labs with over 20 years experience in the Canadian and international pharmaceutical industries. David has a wealth of experience in driving strategic change in complex and ambiguous environments. His previous roles within the pharmaceutical industry have centred around transformation, portfolio and channel diversification, and he’s been recognized for driving significant revenue and profit growth during his tenures. David prides himself in being a people-centric leader who has been able to increase employee engagement while transforming multi-national organizations.

David holds an EMBA from the Kellogg School of Business at Northwestern University, and an Honors BBA from Wilfred Laurier University.

Shelley Potts
Independent Director

Shelley is the former President and CEO of Nestlé Canada and a consumer packaged goods industry top executive with an outstanding track record of success. Ms. Martin served in a variety of senior executive roles at Nestlé Canada Inc. from 1990 until she retired after five years as President and Chief Executive Officer in 2018. During her time leading Nestlé Canada, she drove a substantial increase in revenue, market share and profitability and transformed core business units and brands by introducing new formulas, packaging, pricing, global sources of supply and Lean (Six Sigma) tools. In 2018, Nestlé Canada’s annual sales were approximately $2.6 billion. She began her career at General Mills Canada in 1985 and was named one of Canada’s Most Powerful Women by the Women’s Executive Network (WXN) in 2015, 2016 and 2018. Ms. Martin is a member of the Advisory Board of Moosehead Breweries as well as Crosby Molasses, and is a Director of Vineland Research and Innovation Centre, a leader in horticultural research and innovation. From 2016 to 2018, she served as Board Chair of Food & Consumer Products of Canada (FCPC), which represents more than 100 food, beverage, and consumer product manufacturers of all sizes. From 2013 to 2018, she was a Director of The Grocery Foundation, a not-for-profit organization that has raised over $90 million for student nutrition programs. Ms. Martin is a graduate of Wilfrid Laurier University (Bachelor of Business Administration) and earned the Institute of Corporate Directors ICD. D designation in 2016.

Chris Halyk
Independent Director

Mr. Halyk has 35 years of pharmaceutical industry experience including 33 years with Johnson & Johnson. Among his many career highlights, he served as: Vice-President, Sales and Marketing and a member of the Janssen Management Board with responsibility for innovations in direct-to-consumer advertising, patient education and sales force automation; Managing Director of Ortho Biotech, the biopharmaceutical division of Janssen Inc.; and from 2006 until his retirement in 2019 as the President of Janssen Inc. (Canada) where under his leadership, the company became the largest pharmaceutical company in Canada. During his tenure, his accomplishments included, bringing innovative products, services and solutions to market along with new technologies and treatments in oncology, immunology, neuroscience, infectious diseases and vaccines, cardiovascular and metabolism and pulmonary hypertension. Mr. Halyk holds an Honours Business Administration degree from Ivey Business School at Western University. He served as the Chair of the Board of Directors for Rx&D, the industry association for Canada’s Research-Based Pharmaceutical Companies (now named Innovative Medicines Canada) from 2012 until 2013. Before joining Johnson & Johnson, Mr. Halyk worked for pharmaceutical company Warner-Lambert in Toronto.

Dr. Michael Bumby
Independent Director

Dr. Michael Bumby has been appointed to the MediPharm Labs Board of Directors, effective April 1, 2023. Michael served as the Chief Financial Officer of VIVO for over 5 years prior to MediPharm Labs acquiring VIVO Cannabis. Michael has over 20 years of experience in pharmaceuticals with more than 10 years spent internationally with Eli Lilly. He has held previous CFO roles with multiple, NASDAQ and TSX listed public Canadian biotech companies.

Stock Data

Stock Quote

Medipharm Labs Corp
Toronto Stock Exchange: LABS:CA

Detailed Information

Today
Current Date
Last
Price
% Chg
Price
High
Price
Volume
Quantity
Open
Price
Low
Price
Change
Price
Prev. Close
Price
Share Information
Year High
Price
Shares Out
Price
VWAP
Price
Year Low
Price
Market Cap
Price
Exchange
TSX
PB Ratio
ratio

Stock Quote

Medipharm Labs Corp
OTCQB Marketplace: MEDIF:US

Detailed Information

Today
Current Date
Last
Price
% Chg
Price
High
Price
Volume
Quantity
Open
Price
Low
Price
Change
Price
Prev. Close
Price
Share Information
Year High
Price
Shares Out
Price
VWAP
Price
Year Low
Price
Market Cap
Price
Exchange
OTCQB
PB Ratio
ratio

Stock Quote

Medipharm Labs Corp
Berlin: MLZ:BE

Detailed Information

Today
Current Date
Last
Price
% Chg
Price
High
Price
Volume
Quantity
Open
Price
Low
Price
Change
Price
Prev. Close
Price
Share Information
Year High
Price
Shares Out
Price
VWAP
Price
Year Low
Price
Market Cap
Price
Exchange
BE
PB Ratio
ratio

Firm

Analysts

Email

AltaCorp Capital
David Kideckel
DKideckel@altacorpcapital.com
Canaccord Genuity
Matthew Bottomly
mbottomley@cgf.com
Mackie Research Capital Corporation
Greg McLeish
gmcleish@mackieresearch.com
Roth Capital Partners
Scott Fortune
sfortune@roth.com
Scotia Capital Inc.
Adam Buckham
adam.buckham@scotiabank.com

All analyst coverage is conducted by third parties. Please note that any opinions, estimates or forecasts regarding MediPharm Labs' performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of MediPharm Labs or its management. MediPharm Labs does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. As such the content of any analyst coverage should not be considered financial advice or forecasting that is approved or endorsed by MediPharm Labs.

Sedar

MediPharm Labs Corp.
Learn More

Financial results

Q4 and FY 2023

Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2023

Q3 2023

Q3
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2023

Q2 2023

Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2023

Q4 and FY 2022

Fiscal Year Ended Dec 31, 2022
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2022

Q3 2022

Quarter Ended Sep 30, 2022
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2022

Q2 2022

Quarter Ended Mar 31, 2022
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2022

Q1 2022

Quarter Ended Mar 31, 2022
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2022

FY 2021

Fiscal Year Ended Dec 31,2021
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2021

Q3 2021

Quarter Ended Sep 30, 2021
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2021

Q2 2021

Quarter Ended Jun 30, 2021
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2021

Q1 2021

Quarter Ended Mar 31, 2021
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2021

FY 2020

Fiscal Year Ended Dec 31, 2020
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2020

Q3 2020

Quarter Ended Sep 30, 2020
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2020

Q2 2020

Quarter Ended Jun 30, 2020
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2020

Q1 2020

Quarter Ended Mar 31, 2020
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2020

FY 2019

Fiscal Year Ended Dec 31, 2019
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2019

Q3 2019

Quarter Ended Sep 30, 2019
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2019

Q2 2019

Quarter Ended Jun 30, 2019
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2019

Q1 2019

Quarter Ended Mar 31, 2019
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2019

FY 2018

Fiscal Year Ended Dec 31, 2018
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2018

Q3 2018

Quarter Ended Sep 30, 2018
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2018

Q1 2023

Q1
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2023

Q1 2024

2024
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2024

Q2 2024

2024
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2024
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Corporate Governance

Governance Statement

The Board of Directors of MediPharm Labs Corp. (the “Company”) sets high standards for the Company’s service providers, employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company’s business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Governance at a Glance
Chair
Member
Board Member
Audit
Compensation
Corporate Governance
and Nomination
Science
Chris taves
Chris Halyk
Shelley Martin
Miriam McDonald
Michael Bumby
Board Committees
Chair
Member
Audit Committee
Position
Michael Bumby
Miriam McDonald
Chris Taves
Audit Committee Charter
Compensation Committee
Position
Chris Halyk
Shelley Martin
Michael Bumby
Compensation Committee Charter
Corporate Governance and Nomination Committee
Position
Chris halyk
Shelley Martin
Michael Bumby
Corporate Governance and Nomination Committee Charter
Science Committee
Position
Chris taves
Shelley Martin
Miriam McDonald